23
August 2024
VENTURE LIFE GROUP
PLC
("Venture
Life", "VLG" or the "Group")
Exercise of Options, Director Dealings
and Total Voting Rights
Venture Life (AIM: VLG), a leader in
developing, manufacturing and commercialising products for the
international self-care market, announces that, on 21 August 2024,
it has issued 404,599 new ordinary shares of 0.3 pence each in the
capital of the Company ("Ordinary Shares") following an exercise of
options pursuant to the Company's Long-Term Incentive Plan ("LTIP")
by Jerry Randall (Chief Executive Officer) and Gianluca Brugati
(Chief Manufacturing Officer) (together the "Exercising
Directors").
Following the option exercise
described above, the Exercising Directors' beneficial interests in
the Company are set out below:
|
Exercising Director
|
Current shareholding
|
Options exercised
|
Resultant shareholding
|
|
Jerry Randall
|
2,483,333
|
224,274
|
2,707,607
|
|
Gianluca Brugati
|
3,742,730
|
180,325
|
3,923,055
|
Application has been made to the
London Stock Exchange for the 404,599 new Ordinary Shares to be
admitted to trading on AIM ("Admission") and it is expected that
Admission will become effective and trading will commence at 8.00
a.m. on 29 August 2024.
Following Admission, the total
number of Ordinary Shares in issue will be 127,052,312 and the
total number of voting rights will therefore be 127,052,312. This
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
share capital of the Company under the FCA's Disclosure and
Transparency Rules.
For
further information, please contact:
Venture Life Group
PLC
+44 (0) 1344 578004
Jerry Randall, Chief Executive
Officer
Daniel Wells, Chief Financial
Officer
Cavendish Capital Markets Limited (Nomad and
Broker)
+44 (0) 20 7720 0500
Stephen Keys / Camilla Hume
(Corporate Finance)
Michael Johnson (Sales)
About Venture Life (www.venture-life.com)
Venture Life is an international
consumer self-care company focused on developing, manufacturing and
commercialising products for the global self-care market. With
operations in the UK, Italy, The Netherlands and Sweden, the
Group's product portfolio includes some key products such as the
UltraDEX and Dentyl oral care product ranges, the Balance Activ
range in the area of women's intimate healthcare, the Lift and
Glucogel product ranges for hypoglycaemia, Gelclair and Pomi-T for
oncology support, Earol for ear wax removal, products for fungal
infections and proctology, and dermo-cosmetics for addressing the
signs of ageing. Its products are sold in over 90 countries
worldwide.
The products, which are typically
recommended by pharmacists or healthcare practitioners, are
available primarily through pharmacies and grocery multiples. In
the UK and The Netherlands these are supplied direct by the company
to retailers, elsewhere they are supplied by the Group's
international distribution partners.
Through its two Development &
Manufacturing operations in Italy and Sweden, the Group also
provides development and manufacturing services to companies in the
medical devices and cosmetic sectors.
The
Company makes the following disclosures in accordance with article
19(3) of the Market Abuse Regulation:
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Jerry Randall
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Venture Life Group plc
|
|
b)
|
LEI
|
213800S8CZUPLAB2KC70
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of 0.3p each in
Venture Life Group plc
GB00BFPM8908
|
|
b)
|
Nature of the transaction
|
Exercise of share options
|
|
c)
|
Price(s) and volume(s)
|
224,274 Ordinary Shares at
0.3 pence per Ordinary
Share
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
n/a
|
|
e)
|
Date of the transaction
|
21 August 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Gianluca Brugati
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Manufacturing
Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Venture Life Group plc
|
|
b)
|
LEI
|
213800S8CZUPLAB2KC70
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares of 0.3p each in
Venture Life Group plc
GB00BFPM8908
|
|
b)
|
Nature of the transaction
|
Exercise of share options
|
|
c)
|
Price(s) and volume(s)
|
180,325 Ordinary Shares at
0.3 pence per Ordinary
Share
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
n/a
|
|
e)
|
Date of the transaction
|
21 August 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange
|